MetaCap

Coya Therapeutics Inc. (COYA)

NASDAQ: COYAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.95-0.03 (-1.01%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

COYA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$69.20M
EPS (TTM)
-$1.39
52-week range
2.72 – 6.62
Day range
2.90 – 3.11
Volume / Avg
138.27K / 149.18K
Beta
—

52-week range

$2.72$6.62

COYA stock today

Shares of Coya Therapeutics (COYA) finished lower on Nov 20 at $2.95, a drop of 1.01% or $0.03 per share, versus the S&P 500's 3.70% decline. At this level, COYA sits near the bottom of its 52-week range of $2.72 to $6.62: 55.4% below the high, set on Dec 1, 2025 and 8.5% above the low. COYA is down 49.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 50.7%.

Coya Therapeutics has posted a net loss over the last twelve months (EPS of -$1.39), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Coya Therapeutics

Company profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Arun Swaminathan Ph.D.
Headquarters
Houston, TX
Employees
8
IPO year
2022

Financial highlights

Full financials

In fiscal 2025, Coya Therapeutics generated $7.9 million in revenue, up 123.6% from fiscal 2024. Coya Therapeutics reported a net loss of $21.2 million, compared with a loss of $14.9 million a year earlier. Operating margin was -283.9%.

Coya Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$7.95M$3.55M$6.00M$0—
Growth+123.57%-40.79%———
Net income$-21.23M$-14.88M$-7.99M$-12.24M$-4.89M
EPS (diluted)$-1.27$-0.98$-0.79$-4.73$-1.89

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$15.21+415.59%

  • Strong buy 0
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $18.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.45 vs $-0.35
Surprise
-28.57%

COYA news

All COYA news

Coya Therapeutics peers

Health Care sector
COYA peer companies
CompanyPrice% ChgMarket capCompare
ZYBTZhengye Biotechnology Holding Limited Class A1.48-2.63%$70.14Mvs COYA
MAIAMAIA Biotechnology Inc.1.11-2.63%$68.54Mvs COYA
CINGCingulate Inc.4.51-14.26%$67.48Mvs COYA
MNOVMedicinova Inc1.31+3.15%$67.11Mvs COYA
PLYXPolaryx Therapeutics Inc.1.33-11.92%$66.30Mvs COYA
PMVPPMV Pharmaceuticals Inc.0.876-33.13%$66.17Mvs COYA
GOSSGossamer Bio Inc.10.72-4.54%$65.57Mvs COYA
FBIOFortress Biotech Inc.1.90+7.34%$64.11Mvs COYA

Indexes, lists and sector

Coya Therapeutics stock FAQ

What is Coya Therapeutics's stock price today?

COYA last traded at $2.95 as of Nov 20, 4:00 PM EST, down 1.01% on the day. Prices are delayed at least 15 minutes.

Who is Coya Therapeutics's CEO?

Dr. Arun Swaminathan Ph.D. is the chief executive officer of Coya Therapeutics Inc., which has about 8 employees.

What is the COYA 52-week high?

The 52-week high for COYA is $6.62 and the 52-week low is $2.72. The stock is currently 55.4% below its high.

Compare COYA